Results 201 to 210 of about 752,656 (293)

Menopausal status at the age of 46: Its association with depressive and anxiety symptoms and morbidity in women—A northern Finland birth cohort 1966 study

open access: yesActa Obstetricia et Gynecologica Scandinavica, EarlyView.
Women who are perimenopausal or menopausal at age 46 have a higher risk of anxiety and depressive symptoms than premenopausal women. Early‐onset menopause highlights the need for mental health support during and after the menopausal transition. Abstract Introduction The incidence of several morbidities increases during the menopausal transition ...
Tiia Saarinen   +4 more
wiley   +1 more source

Prevalence and ultrasonographic characterization of newly detected findings suggestive of deep and ovarian endometriosis in postmenopausal women undergoing routine gynecological examination

open access: yesActa Obstetricia et Gynecologica Scandinavica, EarlyView.
Ultrasound findings suggestive of deep and ovarian endometriosis were identified in 8.1% of postmenopausal women without a previous diagnosis. Posterior nodules were more frequent within 5 years of menopause and were associated with a history of reproductive‐age pain, but not with current pelvic pain or dyschezia.
Fabio Barra   +9 more
wiley   +1 more source

Gold‐standard evidence and best practice guidance for menstrual cycle‐informed clinical care: An overview for clinicians

open access: yesBritish Journal of Clinical Psychology, EarlyView.
Abstract Objectives To synthesize current evidence and provide clinically actionable recommendations for integrating menstrual cycle‐related processes—particularly hormone sensitivity, Premenstrual Dysphoric Disorder (PMDD) and Premenstrual Exacerbation (PME)—into psychological assessment, formulation and treatment.
Ellen R. Lambert   +2 more
wiley   +1 more source

Current Approaches to Support Patients to Withdraw From Image and Performance Enhancing Drugs

open access: yesClinical Endocrinology, EarlyView.
ABSTRACT Image and performance‐enhancing drugs (IPEDs) include agents such as androgens, growth hormone, and erythropoietin, which are used to enhance appearance and physical performance. Androgens, also known as anabolic‐androgenic steroids (AAS), are the most used IPEDs worldwide.
Elizabeth Hyams   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy